Cannabinoids CB2 Receptors, One New Promising Drug Target for Chronic and Degenerative Pain Conditions in Equine Veterinary Patients.

This study investigates the potential of using cannabinoid CB2 agonists, specifically from the Cannabis sativa plant, as a new means of treating chronic and degenerative pain conditions in equine patients which do not result in the psychoactive effects typically associated with cannabinoids.

Study Background and Current Treatment Limitations

• The research focuses on osteoarticular diseases in horses, a prevalent issue often treated with steroids and nonsteroidal anti-inflammatories.
• However, these medications can cause a variety of side effects. There is thus a demand for alternative treatments for such conditions.
• The study offers cannabinoids, specifically cannabinoid CB2 agonists synthesized by the Cannabis sativa plant, as possible solutions.

Cannabinoids and Receptors

• Cannabinoids are known for their psychoactive properties; they are produced by the marijuana plant.
• In animals, two primary receptors for cannabinoids have been identified. These are the cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2).
• Activation of these receptors leads to various physiological responses, including modulation of nociception—or pain perception.

Opportunities with Cannabinoid CB2 Receptors

• Recently, the use of synthetic cannabinoid type 2 receptor agonists has been proposed.
• Unlike CB1 receptors, activating CB2 receptors seems to offer pain-relieving (antinociceptive) properties without the usual psychoactive effects associated with cannabinoids.
• This could make CB2 receptors an excellent drug target for chronic and degenerative pain conditions in equine animals, such as osteoarthritis.
• The use of these CB2 agonists may overcome current limitations, such as patient individualities and side effects from conventional treatments, that prevent optimal pain management.